SCHEDULE: Caligan Partners Discloses SAB Biotherapeutics Stake
Beneficial Ownership Filing
Caligan Partners LP and David Johnson have reported beneficial ownership of 10.4% of SAB Biotherapeutics, Inc. common stock as of March 31, 2026.
Summary
- Caligan Partners LP and David Johnson, through Caligan Funds and Accounts, collectively beneficially own 7,967,207 shares of SAB Biotherapeutics, Inc. common stock.
- This ownership stake represents 10.4% of the company's outstanding common stock as of May 6, 2026.
- The filing is made under Schedule 13G, indicating the reporting persons are not attempting to influence or change the control of the issuer.
- The reporting persons are identified as an investment adviser (IA) and a holder of a significant stake (PN) for Caligan Partners LP, and a holder of a significant stake (HC) and an individual (IN) for David Johnson.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing. It is a standard disclosure of beneficial ownership and does not inherently signal positive or negative developments for the company, but rather the investment position of Caligan Partners LP.
Positives
- Caligan Partners LP and David Johnson have disclosed a significant ownership stake, providing transparency to the market.
- The filing indicates that the shares were acquired and are held in the ordinary course of business, suggesting a passive investment approach.
Future Outlook
The filing does not contain forward-looking statements or guidance. It is a disclosure of beneficial ownership.
Industry Context
StockSavvy.ai notes that Schedule 13G filings are common for institutional investors and significant individual holders who acquire substantial stakes in public companies. This filing indicates Caligan Partners LP's investment in SAB Biotherapeutics, Inc., a biotechnology company, which aligns with typical investment strategies in the sector.
Stakeholder Impact
- Shareholders: Increased transparency regarding significant ownership, potentially influencing market perception and trading activity.
- Management: Awareness of a substantial passive investor, which may be considered in future strategic decisions.
- Creditors: No direct impact indicated by this filing.
Key Dates
| Date | Description |
|---|---|
| 03/31/2026 | Date of event requiring filing of this statement (ownership as of this date). |
| 05/06/2026 | Date as of which shares outstanding were calculated for percentage calculation. |
| 05/12/2026 | Date SAB Biotherapeutics, Inc. filed its Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2026. |
| 05/15/2026 | Date of certification and signature for the Schedule 13G filing. |
Keywords
Schedule 13G, SAB Biotherapeutics, Caligan Partners LP, David Johnson, Beneficial Ownership, Common Stock, Investment Management, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.